The bias against Central Nervous System (CNS) drug development manifests itself in approval trends by regulatory agencies. Certain drugs are "fast-tracked" for approval due to perceived medical importance, notably those that can potentially treat severe or life-threatening illnesses that address an unmet medical need. Given the lack of effective treatments, the growing number of treatment-refractory CNS patients, and the high degree of intolerable side-effects, many CNS development programs would be considered to address an unmet medical need. Although most companies enter into CNS development programs fully aware of these complexities, they are often minimized or even ignored in favor of the potential payoff of a CNS drug approval, given the enormous and ever-growing CNS customer base. To address such impediments, Bordeaux-based contract research organization EphyX Neuroscience—specialized in electrophysiology for neuroscience-related preclinical studies and drug discovery—offers the highest quality electrophysiological measurements in human iPS cells-derived neuronal cultures and acute slice preparations from a vast diversity of rodents and human brain areas. The company designs the most relevant protocols and provides its customers with the best possible services in terms of data quality, speed of acquisition, human interactions, and scientific exchange. "EphyX applies the technique of electrophysiology to induced pluripotent stem cells (iPSC) to help clients drastically limit the rate of failure in CNS-related early preclinical studies and drug discovery," states Txomin Lalanne, the President, and Co-Founder at EphyX Neuroscience.

A team of highly qualified personnel that know the nitty-gritty behind delivering reliable neuroscience research services, the company effectively empowers its clients to harness the highest quality of electrophysiological measurements in rodent acute slices/dissociated cultures and human iPSC-derived neuronal cultures.